Abstract
Axitinib, an oral small-molecule tyrosine kinase inhibitor targeted to angiogenesis, has demonstrated activity in advanced renal cell carcinoma. Common side effects include hypertension, fatigue and dysphonia. Axitinib is currently awaiting approval as a second-line agent in the treatment of advanced renal cell carcinoma. Trials, which include treatment-naive patients, are ongoing and will study the benefit of axitinib in the first-line setting.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1247-1253 |
| Number of pages | 7 |
| Journal | Future Oncology |
| Volume | 7 |
| Issue number | 11 |
| DOIs | |
| State | Published - Nov 2011 |
Keywords
- AG 013736
- AXIS
- VEGF
- angiogenesis
- axitinib
- renal cell carcinoma
- targeted therapy
ASJC Scopus subject areas
- Oncology
- Cancer Research